Limitless Possibilities
Through Exquisite Control
Regulating
Immune Response
Our first-in-class medicines precisely control or enhance immune responses across disease indications.
A Leading Portfolio of
First-in-Class Small Molecules
We are working with a sense of urgency to develop novel drugs that meet the needs of patients with inflammation-driven diseases and cancer.
An Unprecedented Track Record
Since the inception of IFM, we have advanced multiple, novel programs from discovery to first-in-human studies and beyond.
IFM Therapeutics Has an Unprecedented Track Record
Among the team's achievements in the company's first 3.5 years has been the progression of 3 novel programs from the standing start through to the clinic and the closing of 2 major deals.
2015
October
IFM Therapeutics founded to discover agonists of NLRP3 for cancer.
2016
FEBRUARY
Novel and proprietary NLRP3 agonist leads identified
MAY
Novel and proprietary STING agonists discovered
JUNE
IFM Therapeutics's $27M Series A closed
2017
SEPTEMBER
Preclinical PoC for both NLRP3 and STING agonists demonstrated
SEPTEMBER
$2.32B sale of IFM Uno to BMS closed; IFM Therapeutics, LLC created as a spin-out, and IFM Tre launched
2018
FEBRUARY
BMS dosed initial patient with first-in-class NLRP3 agonist, IFM-1222
JULY
IFM Tre's $31M Series A financing closed (focus on NLRP3 antagonist)
2019
FEBRUARY
IFM Due launched (focus on cGAS/STING antagonists)
MARCH
IFM Tre dosed initial subject with first-in-class NLRP3 antagonist, IFM-2427
APRIL
BMS dosed first patient with STING agonist, IFM-1364
MAY
$1.575B sale of IFM Tre to Novartis closed
NOVEMBER
IFM Quattro and IFM Discovery launched with $55.5M financing from Omega Funds, Atlas Venture and Abingworth
2021
SEPTEMBER
Start of Phase 2 investigating NLRP3 antagonist IFM-2427/DFV890 in familial cold auto-inflammatory syndrome (FCAS)
SEPTEMBER
Start of Phase 2a investigating DFV890 in patients with symptomatic knee osteoarthritis
2023
MAY
Start of Phase 1b Assessing DFV890 in adult patients with myeloid diseases
OCTOBER
Start of Phase 2a investigating DFV890 for inflammatory marker reduction in adult participants with coronary heart disease and elevated hsCRP
2024
FEBRUARY
Start of phase 2a investigating DFV890 for inflammatory marker reduction in an adult population with coronary heart disease and clonal hematopoiesis of indeterminate potential (CHIP)
FEBRUARY
$835M sale of IFM Due to Novartis
